Having established thus far that AMPK regulates BCSC stemness and drug-resistance phenotypes, we wondered whether combinatorial targeting of this adaptive stress kinase, along with administration of the standard chemotherapeutic drug doxorubicin, would benefit breast cancer patients. This evidence concerns the gene PRKAA2 and breast cancer.